Literature DB >> 11920390

Targeting interleukin-1 in the treatment of rheumatoid arthritis.

Jean-Michel Dayer, Barry Bresnihan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11920390     DOI： 10.1002/art.10168

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  24 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; C E Antoni; J W J Bijlsma; G R Burmester; B Cronstein; E C Keystone; A Kavanaugh; L Klareskog
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Authors:  M C Hochberg; J K Tracy; M Hawkins-Holt; R H Flores
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Role of Sp1 transcription factor in Interleukin-1-induced ADAMTS-4 (aggrecanase-1) gene expression in human articular chondrocytes.

Authors:  Judith Sylvester; Rasheed Ahmad; Muhammad Zafarullah
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

5.  Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.

Authors:  J J Haringman; D M Gerlag; A H Zwinderman; T J M Smeets; M C Kraan; D Baeten; I B McInnes; B Bresnihan; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-12-02       Impact factor: 19.103

6.  Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model.

Authors:  Ping Song; Chuanxu Yang; Jesper Skovhus Thomsen; Frederik Dagnæs-Hansen; Maria Jakobsen; Annemarie Brüel; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2019-05-15       Impact factor: 11.454

Review 7.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

8.  Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma.

Authors:  R Ahmad; H Y Qureshi; M El Mabrouk; J Sylvester; M Ahmad; M Zafarullah
Journal:  Ann Rheum Dis       Date:  2006-12-19       Impact factor: 19.103

9.  Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.

Authors:  Lynda E Polgreen; Richard K Vehe; Kyle Rudser; Alicia Kunin-Batson; Jeanine Jarnes Utz; Patricia Dickson; Elsa Shapiro; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-01-28       Impact factor: 4.797

10.  Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes.

Authors:  Yi-Kun Mou; Ping-Ping Zhang; Qiu-Xia Li; Zhi-Ming Lin; Ze-Tao Liao; Qiu-Jing Wei; Jie-Ruo Gu
Journal:  Clin Rheumatol       Date:  2015-04-26       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.